Q1 26 EPS
$2.03
BEAT +6.30%
Est. $1.91
Q1 26 Revenue
$6.96B
BEAT +0.51%
Est. $6.92B
vs S&P Since Q1 26
+1.2%
BEATING MARKET
GILD +5.2% vs S&P +4.0%
Market Reaction
Did GILD Beat Earnings? Q1 2026 Results
Gilead Sciences delivered a mixed first quarter for fiscal 2026, beating on the bottom line while falling short on revenue. The Foster City-based drugmaker posted non-GAAP diluted EPS of $2.03, clearing the $1.94 consensus by 4.60%, though total reve… Read more Gilead Sciences delivered a mixed first quarter for fiscal 2026, beating on the bottom line while falling short on revenue. The Foster City-based drugmaker posted non-GAAP diluted EPS of $2.03, clearing the $1.94 consensus by 4.60%, though total revenues of $6.96 billion came in 5.87% below estimates and slipped 1.7% from a year earlier, weighed down by a 52% collapse in Veklury sales to $144.00 million as COVID-19 hospitalizations declined. The more telling story was the underlying base business, where the HIV franchise grew 10% to $5.03 billion, anchored by Biktarvy at $3.36 billion and bolstered by $166.00 million in first-quarter sales from newly launched Yeztugo. Non-GAAP product gross margins expanded 200 basis points to 87.5%, helping drive a 12% year-over-year EPS gain. Looking ahead, Gilead raised full-year product sales guidance to $30.00 to $30.40 billion, but guided to a non-GAAP loss of $0.65 to $1.05 per share, reflecting roughly $11.50 billion in anticipated IPR&D charges tied to the Arcellx, Ouro Medicines, and Tubulis acquisitions.
Key Takeaways
- • HIV product sales grew 10% driven by higher demand and average realized price
- • Biktarvy sales increased 7% on higher demand and pricing
- • Descovy sales surged 38% on higher average realized price and demand
- • Successful Yeztugo launch contributing $166 million in first quarter of sales
- • Trodelvy grew 37% on higher demand, favorable inventory dynamics and pricing
- • Livdelzi ramped to $133 million from $40 million a year ago
- • Non-GAAP product gross margin expanded 200 bps to 87.5% due to royalty obligation expiration and product mix
- • Lower acquired IPR&D expenses ($107 million vs $253 million year-over-year)
GILD YoY Financials
Q1 2026 vs Q1 2025, source: SEC Filings
GILD Revenue by Segment
With YoY comparisons, source: SEC Filings
GILD Revenue by Geography
With YoY comparisons, source: SEC Filings
“Gilead teams have delivered another strong quarter with 8% year-over-year growth in our base business and 10% growth in HIV, supported by the successful launch of Yeztugo. We have raised our full year revenue guidance as a reflection of our performance.”
— Daniel O'Day, Q1 2026 Earnings Press Release
GILD Earnings Trends
GILD vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
GILD EPS Trend
Earnings per share: estimate vs actual
GILD Revenue Trend
Quarterly revenue: estimate vs actual
GILD Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | $-7.25 | — | — | — | — |
| Q1 26 BEAT | $1.91 | $2.03 | +6.30% | $6.96B | +0.51% |
| Q4 25 BEAT FY | $1.83 | $1.86 | +1.88% | $7.93B | +3.21% |
| FY Full Year | $8.12 | $8.15 | +0.40% | $29.44B | +0.82% |
| Q3 25 BEAT | $2.14 | $2.47 | +15.67% | $7.77B | +4.14% |
| Q2 25 BEAT | $1.96 | $2.01 | +2.72% | $7.08B | +1.69% |
| Q1 25 BEAT | $1.77 | $1.81 | +2.11% | $6.67B | -2.14% |